ATP1A3 and glioblastoma: In addition, the MGMT promoter methylation status is important in determining TMZ sensitivity in GBM; thus, the possible correlations between CS‐6 treatment and MGMT methylation status, as well as the effect of ATP1A3 on CS‐6‐induced changes in MGMT methylation status, were explored (Figure S1).